TY  - JOUR
AU  - Mok, Tony S
AU  - Cheng, Ying
AU  - Zhou, Xiangdong
AU  - Lee, Ki Hyeong
AU  - Nakagawa, Kazuhiko
AU  - Niho, Seiji
AU  - Chawla, Alka
AU  - Rosell, Rafael
AU  - Corral, Jesus
AU  - Migliorino, Maria Rita
AU  - Pluzanski, Adam
AU  - Noonan, Kay
AU  - Tang, Yiyun
AU  - Pastel, Malaika
AU  - Wilner, Keith D
AU  - Wu, Yi-Long
PY  - 2021
DO  - 10.1007/s40265-020-01441-6
UR  - http://hdl.handle.net/10668/16812
T2  - Drugs
AB  - ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) and an EGFR-activating mutation, reported significant improvement in overall...
LA  - en
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Dose-Response Relationship, Drug
KW  - ErbB Receptors
KW  - Female
KW  - Gefitinib
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Mutation
KW  - Protein Kinase Inhibitors
KW  - Quinazolinones
KW  - Survival Analysis
TI  - Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
TY  - research article
VL  - 81
ER  -